Release Details

TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 19, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008. The presentation will provide an overview of the Company and its clinical programs and is scheduled to be broadcast live on Wednesday, May 21 at 2:30 p.m. Eastern Time. The session may be accessed through the Company's web site (www.regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the presentation. An archived version of the presentation will be available after the live webcast through June 20, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^™ (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

CONTACT: Regeneron Pharmaceuticals, Inc.
Investor Relations, 914-345-7640
invest@regeneron.com
or
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Kimberly Chen, 212-845-5634
kchen@biosector2.com

SOURCE: Regeneron Pharmaceuticals, Inc.